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Stevia rebaudiana Bertoni is a shrub having a high content of sweet diterpenoid glycosides in its leaves, mainly stevioside and
rebaudioside A, which are used as noncaloric, natural sweeteners. The aim of this study was to deepen the knowledge about the
insulin-mimetic eﬀect exerted by four diﬀerent mixtures of steviol glycosides, rich in stevioside and rebaudioside A, in neonatal
rat cardiac ﬁbroblasts. The potential antioxidant activity of these steviol glycosides was also assessed, as oxidative stress is
associated with diabetes. Likewise the insulin eﬀect, steviol glycosides caused an increase in glucose uptake into rat ﬁbroblasts by
activating the PI3K/Akt pathway, thus inducing Glut4 translocation to the plasma membrane. The presence of S961, an insulin
antagonist, completely abolished these eﬀects, allowing to hypothesize that steviol glycosides could act as ligands of the same
receptor engaged by insulin. Moreover, steviol glycosides counteracted oxidative stress by increasing reduced glutathione
intracellular levels and upregulating expression and activity of the two antioxidant enzymes superoxide dismutase and catalase.
The present work unravels the insulin-mimetic eﬀect and the antioxidant property exerted by steviol glycosides, suggesting their
potential beneﬁcial role in the cotreatment of diabetes and in health maintenance.
1. Introduction
Stevia rebaudiana Bertoni is a shrub belonging to the Aster-
aceae family, native to Paraguay and Brazil, and has been
now cultivated in many parts of the world [1–3]. Due to the
high content of sweet diterpenoid glycosides in its leaves,
the “sweet herb of Paraguay” has been used for many years
in South America for sweetening food products and in
traditional medicine, particularly as a natural control for
diabetes [4]. Stevia rebaudiana Bertoni has attracted scien-
tiﬁc interest for its potential use as noncaloric [5, 6] and
noncariogenic [7, 8] sweetener and also for its multifaceted
beneﬁts on human health [9] and therapeutic properties
[10, 11]. Several studies indeed suggest that Stevia has antihy-
perglycaemic, antihypertensive, antitumour, antidiarrheal,
diuretic, anti-inﬂammatory, and immune-modulatory eﬀects
[12]. Owing to these characteristics, leaf extracts rich in
steviol glycosides, such as stevioside and rebaudioside A,
have been authorized as commercial sweeteners and food
additives [13], as the safety of high-purity steviol glycosides
has been extensively reviewed in the published literature
and by national and international food safety agencies [14].
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 3724545, 13 pages
https://doi.org/10.1155/2017/3724545
Since the prevalence of diabetes is rapidly rising all over
the world, the identiﬁcation of nontoxic, natural compounds
from a plant origin, able to mimic the insulin action, appears
to be of great interest and importance, according to the last
WHO expert committee recommendations [15]. In this con-
text, the use of Stevia extracts as natural sweeteners is notably
useful in restricting or controlling caloric intake in the diet or
as a substitute for sucrose in the treatment of diabetes. The
mechanisms by which Stevia leaves and its steviol glycosides
exert a marked antidiabetic eﬀect have been intensively
studied [16]. Some reports account for an increased insulin
secretion by stevioside [17] or rebaudioside A [18]; other
demonstrated that stevioside increases insulin sensitivity in
rodent models [19], inducing antihyperglycaemic eﬀects on
diabetic rats [20] and on diabetic subjects [21, 22]; moreover,
insulin-mimetic properties of steviol and stevioside have
been reported in L6 and 3T3L1 cell lines [23]. Furthermore,
as oxidative stress is among the features correlated with dia-
betic condition, the antioxidant activity recently attributed to
Stevia further highlights the potential synergic beneﬁcial
eﬀect of this plant [24–27].
We previously demonstrated that steviol glycosides exert
a marked insulin-like eﬀect on glucose transport activity in
cancer cell lines [28]. The aim of this study, graphically
reported in Figure 1, was to investigate the molecular mech-
anisms underpinning the insulin-mimetic eﬀect showed by
steviol glycosides in a nontransformed cell system. Moreover,
the potential antioxidant property of steviol glycosides was
also examined. Neonatal rat cardiac ﬁbroblasts were chosen,
as they are fully involved in high glucose-induced cardiac
ﬁbrosis, a pathological consequence of diabetes, leading to
cardiac dysfunction [29]. Cardiac ﬁbroblasts, indeed, express
the insulin receptor (IR) [30], the insulin growth factor-like 1
and its receptor (IGF-1/IGF-1R) [31], and the insulin-
responsive glucose transporter (Glut4) [32].
2. Materials and Methods
2.1. Chemicals and Reagents. Dulbecco’s modiﬁed Eagle’s
medium (DMEM), foetal bovine serum (FBS), penicillin,
streptomycin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT), insulin, 2-deoxy-glucose (DOG),
phloretin, DAPI, RIPA lysis buﬀer, 10% SDS solution, mam-
malian protease inhibitor mixture, phosphatase inhibitor
cocktail PhosSTOP (Roche™), hydrogen peroxide, Tris-
HCl, sodium pyruvate, NADH, monochlorobimane (MCB),
SOD assay kit, primary antibody to β-actin, bovine serum
albumin (BSA), and all other chemicals were purchased from
Sigma-Aldrich. S961 insulin receptor antagonist was from
Phoenix Peptide. 2-Deoxy-D-[2,6-3H]-glucose and Ultima
Gold MV scintillation cocktail were from PerkinElmer.
Anti-Glut4 (sc-1606) antibody was obtained from Santa Cruz
Biotechnology. Rabbit anti-goat IgG (H+L) secondary anti-
body Alexa Fluor® 488 conjugate (A11078) was purchased
from Life Technologies. Primary antibodies against
phospho-Akt (Ser473) (#4058), Akt (#9272), phospho-
AMPKα (Thr172) (#2535), AMPKα (#4058), and IGF-1
receptor β (IGF-1R) (#3027) and horseradish peroxidase-
conjugated secondary antibodies anti-rabbit (#7074) and
anti-mouse (#7076) were purchased from Cell Signaling
Technologies. Primary antibodies anti-phospho-PI3 kinase
p85 pTyr458/p55 pTyr199 (#PA5-17387) and anti-phos-
pho-IGF-1R pTyr1165+pTyr1166 (#PA5-35452) were from
Thermo Scientiﬁc. Anti-PI3 kinase (#06-195) antibody was
purchased from Millipore. DC™ Protein Assay, 4–20%
Mini-PROTEAN® TGX™ Precast Gels, Precision Plus
Protein™ Unstained Standards, and Clarity™ Western ECL
Substrate were from Bio-Rad. Catalase Assay Kit was from
Cayman Chemical. RNA-to-cDNA Conversion Kit was from
Applied Biosystems. RNA Miniprep Kit was from Agilent
Technologies. RT-PCR primers for superoxide dismutase 1
(SOD1), catalase (CAT), β-2-microglobulin (B2M), and
actin (ACT) were manufactured from Sigma-Aldrich.
Four diﬀerent mixtures of steviol glycosides, diﬀering in
their relative content, were provided by Stevia extraction
companies and used in this study.
REB A 97 (R97) was from Pure Circle SDN BHD (Negeri
Sembilan, Malaysia) and, according to the certiﬁcate of
analysis, contains >97% rebaudioside A and <3% other
steviol glycosides.
RA60 (R60) was from HYET Sweet B.V. (Breda, the
Netherlands) and, according to the certiﬁcate of analysis,
contains 95.48% total steviol glycosides, of which 63.43% are
rebaudioside A, 22.85% are stevioside, 8.21% are rebaudioside
C, 0.73% are dulcoside A, and 0.26% are other steviol
glycosides.
SG95 (SG) was from Pure Circle SDN BHD (Negeri
Sembilan, Malaysia) and, according to the certiﬁcate of anal-
ysis, contains >95.0% total steviol glycosides, of which
>50.0% are rebaudioside A and at least 25% are stevioside.
RA50 (TRU) was from Eridania Italia SpA. (Bologna,
Italy) and contains 95.0% total steviol glycosides, of which
at least 50% are rebaudioside A and 25% are stevioside and
20% other steviol glycosides are not analytically quantiﬁed.
The structures of the main steviol glycosides, stevioside
and rebaudioside A, are reported in Figure 2.
2.2. Cell Culture. Neonatal Sprague-Dawley rat cardiac
ﬁbroblasts were a kind gift of Dr. Antonello Lorenzini
(Department of Biomedical and Neuromotor Sciences, Alma
Mater Studiorum—University of Bologna, Italy). Cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% (v/v) foetal bovine serum (FBS),
2mM glutamine, 100U/mL penicillin, and 100μg/mL strep-
tomycin, at 37°C in a humidiﬁed atmosphere maintained at
5% CO2.
2.3. Cell Viability. Cell viability was evaluated by the MTT
assay. Neonatal rat cardiac ﬁbroblasts were treated with
increasing concentrations of R97, R60, SG, and TRU
(0.5–5mg/mL). After 24 h, cells were stressed or not with
100μM H2O2 for 30min and then incubated with
0.5mg/mL MTT for 4 h at 37°C. To dissolve the blue-
violet formazan salt crystals formed, a solubilisation solu-
tion (10% SDS, 0.01M HCl) was added and the plates
were incubated overnight in a humidiﬁed atmosphere
(37°C, 5% CO2) to ensure complete lysis. The absorbance
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at 570 nm was measured using a multiwell plate reader
(Wallac Victor2, PerkinElmer).
2.4. Glucose Transport Assay. Glucose transport assay was
performed as described in [28, 33]. Cells were incubated or
not with R97, R60, SG, or TRU (1mg/mL) for 1 h or with
insulin (100 nM) for 30minutes, in the presence (or not) of
S961 (10nM) for 90min. Then, they were washed in PBS
and treated for 10min at 37°C with a mixture of 2-deoxy-D-
[2,6-3H] glucose (0.8μCi/assay) and 1.0mM unlabeled glu-
cose analogue (DOG), under conditions where the uptake
was linear at least for 20min. The transport was stopped
by adding phloretin (ﬁnal concentration 0.3mM), a potent
inhibitor of glucose transport activity. Cells were washed
twice with PBS, detached and resuspended with 1mL cold
PBS, and added to Ultima Gold MV scintillation cocktail
(PerkinElmer). Radioactivity was measured by liquid
scintillation counting (Tri-Carb® liquid scintillation
analyzer, PerkinElmer).
2.5. Immunoﬂuorescence. Neonatal rat cardiac ﬁbroblasts,
grown on coverslips, were treated with R97 or R60
(1mg/mL) for 1 hour or with insulin (100 nM) for
30min in the presence or absence of 10 nM S961 for 90min
and thenﬁxed in 3% (w/v) paraformaldehyde for 15min.Cells
were washed twice with PBS, blocked with 1% (w/v) PBS/BSA
for1hour, and then incubated for1hourwith20μg/mLofgoat
anti-Glut4 antibody raised against a peptide within an extra-
cellular domain of the glucose transporter protein. Subse-
quently, cells were treated for 1 hour with ﬂuorescent FITC-
conjugated rabbit anti-goat IgG in the dark, nuclei were
stained with DAPI, and coverslips were mounted on slides.
Confocal imagingwas performedby aNikonA1 confocal laser
scanning microscope (Nikon Instruments, Japan).
2.6. Immunoblotting Analysis. After treatments with R97,
R60, SG, or TRU (1mg/mL) for 1 hour or with insulin
(100 nM) for 30min, rat cardiac ﬁbroblasts were washed with
ice-cold PBS and lysed with RIPA buﬀer containing mamma-
lian protease and phosphatase inhibitor mixtures. Protein
concentration was measured by Bio-Rad DC Protein Assay
(Bio-Rad Laboratories). Proteins were separated on 4–20%
SDS-PAGE Mini-PROTEAN TGX Precast Gels using a
Mini-PROTEAN II apparatus (Bio-Rad Laboratories) and
electrophoretically transferred to the nitrocellulose mem-
brane (Hybond-C; GE Healthcare). To avoid nonspeciﬁc
binding, membranes were incubated in blocking buﬀer
containing 5% (w/v) albumin in Tris-buﬀered saline
Insulin-mimetic
properties
Measurement of
glucose uptake in
the absence or
presence of an insulin
receptor inhibitor
Assesment of Glut4
translocation in the
absence or
presence of an insulin
receptor inhibitor
Do steviol glycosides and
insulin share the same
transduction pathway? 
AMPK pathway PI3K/Akt pathway 
Antioxidant
activity
Evaluation of cell
viability 
Evaluation of LDH
activity 
What are the
mechanisms by which
steviol glycosides exert
cellular protective
eects?
Evaluation of CAT
activity 
Evaluation of CAT
expression 
Evaluation of SOD
activity 
Evaluation of SOD
expression 
Measurement of
GSH intracellular
level
Steviol glycosides 
Figure 1: Graphical representation of the experimental design.
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(TBS)/Tween and probed overnight at 4°C with primary
antibodies (anti-phospho-IGF-1R, anti-IGF-1R, anti-phos-
pho-PI3K, anti-PI3K, anti-phospho-Akt, anti-Akt, anti-
phospho-AMPK, anti-AMPK, or anti-β-actin as internal
normalizers). Nitrocellulose membranes were then washed
with TBS/Tween and incubated with horseradish
peroxidase-labelled secondary antibodies in 5% albumin
TBS/Tween at room temperature for 1 hour and successively
washed with TBS/Tween. Chemiluminescence detection was
performed using Clarity Western ECL Substrate (Bio-Rad
Laboratories). Bands were acquired with a CCD imager
(ChemiDoc™ MP System, Bio-Rad) and analyzed by using
Image Lab analysis software (Bio-Rad).
2.7. Lactate Dehydrogenase Assay. Rat ﬁbroblasts were incu-
bated with R97, R60, SG, or TRU (1mg/mL) for 24 hours
and then stressed using 100μM H2O2 for 30min. Lactate
dehydrogenase (LDH) release from cells into the culture
medium was detected by monitoring LDH activity through
a spectrophotometric assay based on the reduction of pyru-
vate to lactate coupled with NADH oxidation to NAD+.
The decrease in absorbance at 340nm resulting from the
oxidation of NADH was monitored at 37°C in a Varian Cary
50 Spectrophotometer.
2.8. Determination of Glutathione (GSH) Levels. Reduced
GSH levels were determined by the monochlorobimane
(MCB) ﬂuorometric assay as previously reported [34, 35].
Brieﬂy, rat cardiac ﬁbroblasts were incubated for 24 hours
with R97, R60, SG, or TRU (1mg/mL) and exposed or not
to 100μM H2O2 for 30min. After treatment, the culture
medium was removed and the cells were washed with cold
PBS and incubated for 30min at 37°C with 50μM MCB in
PBS. The strong ﬂuorescence of the GSH-MCB adduct was
measured in a multiwell plate reader (Wallac Victor2, Perki-
nElmer). Excitation wavelength was 355 nm and emission
wavelength was 460 nm.
2.9. Superoxide Dismutase Assay. Rat cardiac ﬁbroblasts
were incubated for 24 hours with R97, R60, SG, or TRU
(1mg/mL), and then, superoxide dismutase (SOD1) activity
was measured using the SOD Assay Kit provided by Sigma-
Aldrich and following the manufacturer’s instructions. SOD
Assay Kit-WST is a colorimetric indirect assay method based
on Dojindo’s highly water-soluble tetrazolium salt WST-1
(2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt) that is reduced by super-
oxide anion to a stable water-soluble formazan with high
molar absorptivity. The absorbance at 440nm is proportional
to the amount of superoxide anion generated from xanthine
oxidase provided in the kit; SOD activity was quantiﬁed as
inhibition activity by spectrophotometrically following the
decrease in the color development at 440nm in a multiwell
plate reader (Wallac Victor2, PerkinElmer).
2.10. Catalase Assay. Rat cardiac ﬁbroblasts were incubated
for 24 hours with R97, R60, SG, or TRU (1mg/mL), and then,
catalase (CAT) activity was quantiﬁed by Cayman’s Catalase
Assay Kit following the manufacturer’s protocol. This kit,
according to the method of Johansson et al. [34], exploits
the peroxidative activity of CAT, and it is based on the oxida-
tion, catalyzed by CAT, of methanol (the electron donor) in
the presence of an optimal concentration of H2O2. The pro-
duced formaldehyde was measured spectrophotometrically
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Figure 2: Chemical structures of stevioside (a) and rebaudioside A (b).
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with the chromogen Purpald® (4-amino-3-hydrazino-5-mer-
capto-1,2,4-triazole), which reacts with aldehydes producing
purple color. The absorbance was monitored at 540nm in a
multiwell plate reader (Wallac Victor2, PerkinElmer). CAT
activity was calculated from the amount of formaldehyde
produced in the assay.
2.11. Analysis of mRNA Expression by RT-PCR. Total RNA
was extracted from ﬁbroblasts using a commercially available
kit (Absolutely RNA Miniprep Kit, Agilent Technologies),
according to the manufacturer’s instructions. The quantiﬁca-
tion of RNA was performed using a NanoVue Spectropho-
tometer (GE Healthcare) by analyzing at A260/A280 and
A260/A230. mRNA was reverse-transcribed into cDNA
starting from 1μg of total RNA using a high-capacity RNA-
to-cDNA Conversion Kit (Applied Biosystems). The subse-
quent PCRwas carried out in a total volume of 20μL contain-
ing 2μL of cDNA, 10μL SsoAdvanced™ Universal SYBR
Green Supermix (Bio-Rad Laboratories), and 1μL (500 nM)
of each primer. The primers used are as follows: CAT
(forward) 5′-CAAGTTCCATTACAAGACTGAC-3′ and (re
verse) 5′-TAAATGGGAAGGTTTCTGC-3′, SOD (forward)
5′-AATGTGTCCATTGAAGATCG-3′ and (reverse) 5′-CAC
ATAGGGAATGTTTATTGGG-3′, β-actin (forward) 5′-AA
GACCTCTATGCCAACAC-3′ and (reverse) 5′-TGATCTT
CATGGTGCTAGG-3′, and β2-microglobulin (forward) 5′-A
CTGGTCTTTCTACATCCTG-3′ and (reverse) 5′-AGATG
ATTCAGAGCTCCATAG-3′.
All primers were produced by Sigma-Aldrich. β-Actin
and β2-microglobulin were used as reference genes. cDNA
ampliﬁcation was started by activating the polymerase for
30 s at 95°C, followed by 40 cycles of 5 s at 95°C and 30 s at
60°C. A melt curve was run to ensure quality control and
the generation of a single product. Normalized expression
levels were calculated relative to control cells according to
the 2−ΔΔCT method.
2.12. Statistical Analysis. Results are expressed as means
± SD. Diﬀerences among the means were determined by
Bonferroni’s multiple comparison test following one-way
ANOVA and were considered signiﬁcant at p < 0 05.
3. Results
3.1. Eﬀect of Steviol Glycosides on Cell Viability. Rat cardiac
ﬁbroblasts were treated with increasing concentrations of
R97, R60, SG, or TRU (0.5–5mg/mL) for 24 hours to inves-
tigate their direct eﬀect on cell integrity/damage. There was
no observed decrease in the ability of cardiac ﬁbroblasts to
reduce MTT following exposure to the four diﬀerent mix-
tures up to 5mg/mL, indicating the absence of toxicity in this
range of concentrations (data not shown). These results are
in agreement with previously reported data obtained in
diﬀerent cell types [28].
3.2. Eﬀect of Diﬀerent Steviol Glycosides on Glucose Transport
Activity and on Glut4 Translocation to the Plasma
Membrane. Neonatal rat cardiac ﬁbroblasts were incubated
for 1 hour with R97, R60, SG, or TRU (1mg/mL) or with
100 nM insulin and then assayed for glucose transport activity.
Figure 3 shows that all mixtures were able to signiﬁcantly
enhance glucose uptake at a similar extent, and,
interestingly, the increase in glucose transport activity
was comparable to that induced by insulin exposure. To
deeper study the mechanism of glucose transport
induced by steviol glycosides, S961, a 43-amino-acid
biosynthetic peptide antagonist of insulin receptor [36],
was used. Cell preincubation with 10nM S961 completely
abolished the increase in glucose transport due to steviol
glycosides or insulin treatment (Figure 3).
It is well known that insulin induces the translocation
of Glut4 from cytosolic storage vesicles to the plasma
membrane, thereby enhancing glucose transport activity
[37]. Therefore, the translocation of Glut4 to the plasma
membrane following treatment with steviol glycosides or
insulin was assessed by utilizing a Glut4-speciﬁc antibody
targeting an epitope in the extracellular domain near the
N-terminus and visualized through confocal microscopy.
Figure 4 shows the eﬀect of two representative mixtures,
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Figure 3: Eﬀect of diﬀerent steviol glycoside mixtures or insulin on glucose transport activity in rat cardiac ﬁbroblasts in the presence or
absence of the antagonist of the insulin receptor S961. Cells were treated with R97, R60, SG, or TRU (1mg/mL) for 1 hour or with
insulin (100 nM) for 30min, in the presence or absence of 10 nM S961 for 90min. Glucose uptake was assayed as described in the
experimental procedure section. Results are expressed as means± SD of three independent experiments, each performed in triplicate.
Statistical analysis was performed by Bonferroni’s multiple comparison test following one-way ANOVA. ∗p < 0 05 signiﬁcantly
diﬀerent from control cells; °p < 0 05 signiﬁcantly diﬀerent from the corresponding cells not treated with S961.
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R97 and R60, in comparison with that of insulin, in the
presence or absence of the antagonist S961. Results indi-
cate that R97 and R60 are able to induce Glut4 transloca-
tion to the plasma membrane with comparable eﬃciency
and that their eﬀect is similar to that obtained by insu-
lin stimulation. Moreover, cell pretreatment with S961
counteracts the observed Glut4 translocation both in
insulin-stimulated cells and in steviol glycoside-treated cells.
Experiments with SG and TRU revealed similar results, indi-
cating that all the samples share the ability to modulate Glut4
translocationwith the same eﬃciency (data not shown). These
results are in accordance with those obtained in the evaluation
of glucose transport activity.
3.3. Eﬀect of Steviol Glycosides on PI3K/Akt and AMPK
Pathways. To assess whether steviol glycosides exert their
eﬀect on glucose transport activity through the IR or IGF-
1R, the activation of the PI3K/Akt pathway, which mediates
the intracellular signaling triggered by the IR family through
IR substrates [38], was investigated. The eﬀects of R97, R60,
SG, or TRU on activation/phosphorylation of IGF-1R,
PI3K, and Akt were examined by immunoblotting, and the
results are shown in Figure 5. Cell treatment with 1mg/mL
of the four diﬀerent mixtures or with 100 nM insulin caused
a signiﬁcant increase in the phosphorylated isoforms of IGF-
1R, PI3K, and Akt, indicating a common pathway in insulin
and steviol glycoside signaling mechanisms.
The activation of the metabolic pathway regulated by
AMP-activated protein kinase (AMPK) is also known to
increase Glut4 translocation and glucose uptake in the
heart, especially during physical activity [39]. To test the
possible contribution of the AMPK-dependent metabolic
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Figure 4: Eﬀect of R97, R60, or insulin on Glut4 translocation to the plasma membrane in rat cardiac ﬁbroblasts in the presence or absence of
the antagonist of the insulin receptor S961. Cells were treated with R97 or R60 (1mg/mL) for 1 hour or with insulin (100 nM) for 30min in the
presence or absence of 10 nM S961 for 90min. Glut4 translocation to the plasma membrane was detected using immunoﬂuorescence staining
with anti-Glut4 antibody and DAPI nuclear staining as a counterstain. Images were acquired by the Nikon A1 confocal laser scanning
microscope (Nikon Instruments, Japan). The results are representative of two independent experiments.
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pathway to the glucose transport stimulation induced by ste-
viol glycosides, the phosphorylation level of AMPK was
investigated by the immunoblotting technique. Results in
Figure 6 indicate that treatment with R97, R60, SG, TRU,
or insulin did not alter the phosphorylation level of AMPK
in these experimental conditions.
3.4. Evaluation of the Potential Antioxidant Activity of
Steviol Glycosides in Rat Cardiac Fibroblasts. In order to
evaluate a potential antioxidant/protective eﬀect exerted
by the four mixtures under study, ﬁbroblasts were treated
with R97, R60, SG, or TRU for 24 hours, stressed (or not)
by exogenous addition of H2O2, and tested for viability by
the MTT assay (Figure 7(a)). The viability of cells
pretreated with steviol glycosides was signiﬁcantly
increased compared to that of H2O2-treated cells, evidenc-
ing their potential protective role against oxidative stress.
Moreover, lactate dehydrogenase (LDH) activity in the
culture medium was quantiﬁed under stressed conditions,
as a nonspeciﬁc marker of cell damage. As shown in
Figure 7(b), ﬁbroblast pretreatment with steviol glycosides
was able to signiﬁcantly counteract the LDH release from
the cells.
The eﬀect of steviol glycosides was also evaluated on
intracellular glutathione (GSH) level and on the activities of
cytosolic superoxide dismutase (SOD1) and catalase (CAT).
Rat cardiac ﬁbroblasts were pretreated with R97, R60, SG,
or TRU for 24 hours, and then, GSH intracellular levels were
measured. Figure 8(a) shows that basal GSH levels were
signiﬁcantly higher in cells pretreated with steviol glycosides
in respect to controls. When ﬁbroblasts were exposed to
H2O2 (Figure 8(b)), a signiﬁcant decrease in basal GSH levels
occurred, whereas cell pretreatment with steviol glycosides
signiﬁcantly counteracted this GSH depletion, allowing the
maintenance of high GSH levels.
SOD and CAT are considered primary antioxidant
enzymes, directly involved in the removal of ROS. Figure 9
shows that CAT (Figure 9(a)) and SOD1 (Figure 9(b))
activities signiﬁcantly increase in rat ﬁbroblasts treated with
steviol glycosides for 24 hours compared to controls.
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Figure 5: Eﬀect of diﬀerent steviol glycoside mixtures or insulin on the PI3K/Akt pathway in rat ﬁbroblasts. (a) Rat cardiac ﬁbroblasts treated
with R97, R60, SG, or TRU (1mg/mL) for 1 hour or with insulin (100 nM) for 30min were lysed with RIPA buﬀer. Cell lysates were
electrophoresed and immunoblotted with the indicated antibodies, as described in the experimental procedure section. Actin detection
was used as a load control. Immunoblots are representative of three independent experiments. (b) Densitometric analysis of protein
phosphorylation status is expressed as phospho-protein/total protein and reported as folds to control. ∗p < 0 05 signiﬁcantly diﬀerent from
control cells.
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In order to verify whether steviol glycoside was able to
induce an upregulation of these antioxidant enzymes also at
the transcriptional level, ﬁbroblasts treated with 1mg/mL of
R97, R60, SG, or TRU for 24h were lysed and analyzed for
SOD1 and CAT cytosolic mRNA content by reverse tran
scriptase-polymerase chain reaction (RT-PCR). Figure 10(a)
shows that an increase in CAT mRNA amount of about 3-4
folds with respect to that of control is observed upon cell
treatment with the steviol glycosides, and also, SOD1 mRNA
content (Figure 10(b)) is signiﬁcantly increased, although at a
minor extent.
4. Discussion
Stevia rebaudiana Bertoni and its glycosides are known not
only as natural, noncaloric sweeteners but also for their anti-
hypertensive, anti-inﬂammatory, immune-modulatory, and
antihyperglycaemic eﬀects [9]. In particular, the hypoglycae-
mic, antidiabetic, and insulin-like properties of steviol
glycosides have been investigated in 3T3-L1 adipocytes [40],
in L6 myoblasts [21], and in cancer-derived cell lines [28].
In this paper, we focused on the insulin-mimetic and
antioxidant activities of steviol glycosides in neonatal rat
cardiac ﬁbroblasts. We demonstrated that both insulin and
steviol glycosides are able to increase glucose entry into the
cells by activating the PI3K/Akt—but not the AMPK—path-
way, thus inducing Glut4 translocation to the plasma mem-
brane. We also showed that steviol glycosides counteract
oxidative stress increasing GSH levels and SOD and CAT
expressions and activities.
Fibroblasts express the insulin receptor (IR) [41];
furthermore, it has been reported that the IGF-1/IGF-1R
system is crucial in the modulation of rat cardiac ﬁbro-
blast growth [31]. Both IGF-1R and IR receptors belong
to the same family, which includes the IR in two isoforms,
IR-A and IR-B, forming homo- or heterodimers, and in
cells expressing both IR and IGF-1R, also IGF-1R/IR
hybrids [42]. Insulin binds with high aﬃnity both to IR
and IGF-1R [41]. Indeed, as reported in Figure 4, IGF-
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Figure 7: Eﬀect of diﬀerent steviol glycoside mixtures on rat cardiac ﬁbroblast viability/proliferation and lactate dehydrogenase (LDH)
activity. Rat cardiac ﬁbroblasts were treated with R97, R60, SG, or TRU (1mg/mL) for 24 hours; then, cells were stressed (or not) with
100μM H2O2 for 30min. Cell viability/proliferation was evaluated by the MTT assay (a) or by the LDH assay (b). Results are expressed as
means± SD of three independent experiments. Statistical analysis was performed by Bonferroni’s multiple comparison test following one-
way ANOVA. ∗p < 0 05 with respect to the control; °p < 0 05 with respect to control cells treated with H2O2.
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Figure 6: Eﬀects of diﬀerent steviol glycoside mixtures or insulin on AMPK phosphorylation level in rat cardiac ﬁbroblasts. (a) Rat cardiac
ﬁbroblasts treated with R97, R60, SG, or TRU (1mg/mL) for 1 hour or with insulin (100 nM) for 30min were lysed with RIPA buﬀer. Cell
lysates were electrophoresed and immunoblotted with anti-AMPK and anti-phospho-AMPK, as described in the experimental procedure
section. Actin detection was used as a control. Immunoblots are representative of three independent experiments. (b) Densitometric
analysis of AMPK phosphorylation level is expressed as phospho-AMPK/total AMPK and reported as folds to control.
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1R is expressed in rat cardiac ﬁbroblasts and it becomes
phosphorylated upon cell treatment with insulin. Owing
to its physiological role played in cell growth, IGF-1R is
also involved in glucose homeostasis through the PI3K/
Akt pathway, considered the predominant downstream
signaling pathway for the IR family [38].
Given the membership of the two receptors to the
same family and the signal proceeding through a common
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Figure 9: Eﬀect of diﬀerent steviol glycoside mixtures on catalase (CAT) and superoxide dismutase (SOD1) activities in rat cardiac
ﬁbroblasts. Rat cardiac ﬁbroblasts were treated with R97, R60, SG, or TRU (1mg/mL) for 24 hours and then lysed and assayed for CAT
(a) and SOD1 (b), as described in the experimental procedure section. Results are expressed as means± SD of four independent
experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni’s test. ∗p < 0 05 signiﬁcantly diﬀerent
from the control.
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Figure 8: Eﬀect of diﬀerent steviol glycoside mixtures on intracellular GSH levels in rat cardiac ﬁbroblasts. (a) Rat cardiac ﬁbroblasts were
treated with R97, R60, SG, or TRU (1mg/mL) for 24 hours, and then, intracellular GSH levels were measured using the ﬂuorescence
probe MCB as described in the experimental procedure section. (b) Upon pretreatment with steviol glycosides, rat ﬁbroblasts were
exposed to 100μM H2O2 for 30min and then assayed for intracellular GSH levels. Results are expressed as means± SD of four
independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni’s test. ∗p < 0 05
signiﬁcantly diﬀerent from the control; °p < 0 05 signiﬁcantly diﬀerent from control cells treated with H2O2.
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Figure 10: Eﬀect of diﬀerent steviol glycoside mixtures on catalase (CAT) and superoxide dismutase (SOD1) mRNA levels in rat cardiac
ﬁbroblasts. Cells were treated with R97, R60, SG, or TRU (1mg/mL) for 24 hours, and after RNA extraction, the level of CAT mRNA (a)
and SOD1 mRNA (b) was assayed according to the experimental procedure section. Each bar represents the mean± SD of three
independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni’s test. ∗p < 0 05 with
respect to the control.
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downstream pathway, we did not discriminate between
either of receptor engagement upon insulin or steviol gly-
coside stimulation.
The increased phosphorylation level of the receptor
IGF-1R observed upon ﬁbroblast treatment with insulin
or the four diﬀerent mixtures indicates that both insulin
and steviol glycosides are able to activate the PI3K/Akt
pathways. Through this pathway, they signiﬁcantly
increase the glucose uptake by intensifying the traﬃcking
of Glut4 isoform from intracellular stores to the plasma
membrane, thus demonstrating the ability of steviol glyco-
sides to mimic the insulin action.
Similar results were obtained in diabetes-induced myo-
tubes and adipocytes by Bhasker and coworkers [23] who
observed an increased level of the Glut4 protein and glucose
transport, together with an enhanced transcription of Glut4
mRNA upon steviol or stevioside treatment, although
stevioside achieved its eﬃcacy at a higher concentration.
Furthermore, to conﬁrm the possibility that stevioside
and rebaudioside A could act as agonists of the same receptor
engaged by insulin, we used the insulin antagonist S961. This
molecule is a single-chain peptide reported to be a full IR
antagonist [36] and stated to be active with a similar potency
in cells expressing mostly IR or IGF-1R, probably through a
hybrid receptor IR/IGF-1R-mediated response [43]. These
authors described also a mixed agonist/antagonist activity
for S961, depending on the cell type and concentration, and
when using S961 as an IR antagonist in vitro, a concentration
starting from 10nM or above is recommended. In rat ﬁbro-
blasts used in our study, 10 nM S961 behaved as insulin
antagonist and completely abolished both the insulin and
the steviol glycoside eﬀects on glucose transport activity, con-
ﬁrming the ability of these molecules to trigger the PI3K/Akt
signaling pathway through the same insulin receptor.
Insulin and contraction are the two key stimuli that
acutely regulate Glut4 recruitment to the plasma mem-
brane of the heart, and cardiac ﬁbroblast contractility is
one of the characteristics of myocardial remodeling [44].
These two stimuli initiate distinct signaling mechanisms,
but both lead to increased Glut 4 translocation and glu-
cose uptake [39]. The contraction signaling pathway pro-
ceeds through AMPK, and although the downstream
targets mediating Glut4 vesicular traﬃcking have not been
completely identiﬁed, it is known that AMPK stimulation
of glucose transport does not involve downstream activa-
tion of the PI3K/Akt pathway [45]. Since crosstalk
between these two pathways cannot be excluded [46] and
neonatal ﬁbroblasts are isolated from rat heart, the poten-
tial involvement of the AMPK pathway in the observed
enhanced glucose transport exerted by steviol glycosides
was investigated, but the results reported in Figure 6 ruled
out this possibility.
SOD↑
Insulin
IR or IGF-1R
Steviol
glycosides
S961
P 
P 
P 
P 
PI3K P 
Akt P 
Glut4
Glut4 pool
Glucose
Glut4
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Cytosol
Nucleus
CAT ↑
GSH↑
SOD ↑
CAT↑
Figure 11: Insulin-mimetic and antioxidant activities of steviol glycoside mixtures. Steviol glycosides are able to act as ligands of the insulin
receptor (IR or IGF-1R), triggering the PI3K/Akt pathway. The insulin receptor antagonist, S961, blocks the signal induced by both insulin
and steviol glycosides. Upon the receptor activation, steviol glycoside signal leads to Glut4 translocation from intracellular pool to the plasma
membrane, allowing glucose entry into the cell and thus mimicking the insulin action. Steviol glycosides are also able to increase the activity
and the expression of the antioxidant enzymes SOD and CAT, probably through the activation of the same pathway (dashed blue lines).
Moreover, cytosolic GSH levels are signiﬁcantly increased in rat cardiac ﬁbroblasts treated with steviol glycoside mixtures.
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These data support the hypothesis that steviol glyco-
sides are able to mimic the insulin action, explaining, at
least in part, the antidiabetic eﬀect ascribed to Stevia
rebaudiana Bertoni.
However, other mechanisms may be responsible for this
eﬀect; in fact, increased oxidative stress caused by prolonged
hyperglycaemia has also been reported to play a major role in
the pathogenesis of this disease [47]. It is well known that the
permanent hyperglycaemia characterizing diabetes causes
glucose autoxidation and glycation of proteins [48], which
thereby depletes the antioxidant defence system thus
promoting free radical generation. Moreover, advanced
glycation end products and insulin both activate NAD(P)H
oxidases, leading to further ROS production [49]. To this
regard, many authors have reported a direct antioxidant
activity of extracts from leaves of Stevia rebaudiana Bertoni,
owing to the presence of alkaloids, ﬂavonoids, and polyphe-
nols [9]; nevertheless, biological systems may operate via
multiple mechanisms [50]. Indeed, some phytochemicals
exert beneﬁcial eﬀects by triggering adaptive stress response
signaling pathways, resulting in the increased production of
cytoprotective proteins, including antioxidant and phase 2
enzymes, heat shock proteins, growth factors, and protein
generally involved in the regulation of cellular redox homeo-
stasis and energy metabolism [51, 52].
Our data demonstrate that steviol glycosides exhibit a
signiﬁcant protective role against H2O2-induced damage,
supporting ﬁbroblast viability and inhibiting LDH release
from the cells. According to Bender and coworker [24], no
direct antioxidant activity is expected from puriﬁed stevioside
or rebaudioside A, since steviol glycosides can hardly be
absorbed by cells in vitro. In order to clarify the mechanism
responsible for this observed protective eﬀect, we investigated
whether steviol glycosides, by activating the IR/IGF-1R path-
way, can modulate endogenous enzymatic and nonenzymatic
systems involved in the antioxidant equipment at protein
and/or transcriptional level. It has been reported that the
stimulation of IGF-1R upon IGF-1 treatment diminishes the
oxidative stress and apoptotic eﬀect of high dose of H2O2 on
humanumbilical vascular endothelial cells, and it was demon-
strated that this protective eﬀect is mediated by the PI3K/Akt
pathway [53]. Interestingly, a signiﬁcant increase in the basal
GSH intracellular level together with a signiﬁcant enhance-
ment in SODandCATexpressions andactivitieswasobserved
in ratﬁbroblasts upon steviol glycoside treatment.GSHplays a
central role in coordinating the antioxidant defence processes
in the body, and the treatment with steviol glycosides main-
tained its high level also after the stressful actionofH2O2. Since
a decline in the activity of SOD andCAT antioxidant enzymes
together with a reduction in GSH levels was described in
diabetic animals [26, 27], our results suggest that these antiox-
idant eﬀects can contribute to the antidiabetic property exhib-
ited by Stevia rebaudiana Bertoni.
5. Conclusions
In conclusion, steviol glycosides exert pleiotropic eﬀects on
rat cardiac ﬁbroblasts due to their ability to modulate the sig-
naling pathways involved in glucose uptake and upregulation
of the endogenous antioxidant defence system. Figure 11
summarizes the obtained results.
These results suggest a potential role of Stevia rebaudiana
not only as an antihyperglycaemic agent but also as a powerful
cardio protective tool in cardiac ﬁbroblasts that have been
recently deﬁnedas “the renaissance cells” [54] due to their fun-
damental role in maintaining cardiac function.
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